Provided by Tiger Trade Technology Pte. Ltd.

Biofrontera Inc

0.8190
+0.00921.14%
Post-market: 0.81900.00000.00%19:13 EDT
Volume:164.37K
Turnover:130.65K
Market Cap:9.54M
PE:-0.79
High:0.8196
Open:0.8000
Low:0.7600
Close:0.8098
52wk High:1.19
52wk Low:0.5360
Shares:11.65M
Float Shares:9.11M
Volume Ratio:1.29
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0358
EPS(LYR):-1.0358
ROE:-141.30%
ROA:-28.00%
PB:0.91
PE(LYR):-0.79

Loading ...

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

THOMSON REUTERS
·
Feb 17

Biofrontera Raises 2025 EBITDA Outlook While Keeping Revenue Target

TIPRANKS
·
Feb 14

FDA Accepts Biofrontera sNDA Filing for Ameluz PDT in Superficial Basal Cell Carcinoma

Reuters
·
Feb 11

Biofrontera Inc - FDA Sets Pdufa Date for September 28, 2026

THOMSON REUTERS
·
Feb 11

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® Pdt in Superficial Basal Cell Carcinoma

THOMSON REUTERS
·
Feb 11

BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt

Reuters
·
Feb 09

Biofrontera Reports Positive Phase 3 Results for Ameluz PDT in Treating Actinic Keratoses Beyond Face and Scalp

Reuters
·
Feb 09

Biofrontera Inc - to Submit Snda to FDA in Q3 2026

THOMSON REUTERS
·
Feb 09

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® Pdt for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

THOMSON REUTERS
·
Feb 09

Biofrontera Inc - Ameluz Pdt Achieves 45.6% Clearance Rate in Phase 3 Study

THOMSON REUTERS
·
Feb 09

Biofrontera Inc - Primary Endpoint Achieved With Complete Clearance Rate of Ak Lesions

THOMSON REUTERS
·
Feb 09

Biofrontera Inc - Ak Lesion Clearance 73.1% in Fas and 80.3% in PPS

THOMSON REUTERS
·
Feb 09

There's No Escaping Biofrontera Inc.'s (NASDAQ:BFRI) Muted Revenues Despite A 42% Share Price Rise

Simply Wall St.
·
Jan 23

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues Between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

THOMSON REUTERS
·
Jan 13

Biofrontera Inc. Projects 2025 Revenue Growth of Up to 13%

Reuters
·
Jan 13

BRIEF-Biofrontera Announces Data Base Locks For Two Clinical Studies Supporting Key Data And Regulatory Milestones

Reuters
·
Jan 08

Biofrontera Inc. Locks Databases for Key Ameluz PDT Clinical Trials in Actinic Keratosis and Acne Vulgaris

Reuters
·
Jan 08

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

THOMSON REUTERS
·
Jan 08

Biofrontera Inc - Plans to Submit Snda to FDA in Summer 2026

THOMSON REUTERS
·
Jan 08

Biofrontera Inc - Phase 2 Acne Study Results to FDA in Early Q3 2026

THOMSON REUTERS
·
Jan 08